This is a big advance, folks. We've never had a disease-modifying drug for this devastating inherited disease
www.science.org/content/arti...
www.washingtonpost.com/health/2025/...
www.economist.com/science-and-...

YouTube video by BBC News Huntington's disease successfully treated for first time | BBC News

Never thought this would happen in my lifetime.

youtu.be/bhExSMZt1zs?...

AACR Legislative Action Center: Your Voice Matters Directly contact your elected officials about the importance of cancer research, the need for continued funding and the latest lifesaving breakthroughs. In the United States, you can do so by sending ...

www.votervoice.net/Shares/BAAAA...

Tissue-resident memory CD8 T cell diversity is spatiotemporally imprinted - Nature Profiling of the location and transcriptome of tissue-resident memory CD8 T cell formation at single-transcript resolution finds regionalized signalling as the basis of immune diversity in t...

It turns out the immune system is playing 4D chess while we thought it was just playing checkers. Using #spatialtranscriptomics from @10xgenomics.bsky.social and @vizgen.bsky.social we were able to peek into the secret lives of tissue resident T cells in the gut as they form after infection 1/n

FastReseg: using transcript locations to refine image-based cell segmentation results in spatial transcriptomics Spatial transcriptomics (ST) is a rapidly advancing field, yet it is challenged by persistent issues with cell segmentation accuracy, which can bias biological interpretations by making cells appear m...

FastReseg: using transcript locations to refine image-based cell segmentation results in spatial transcriptomics, from Broker Spatial Biology, former NanoString
www.biorxiv.org/content/10.1...

@pkrugman.bsky.social how does it feel to hang it up after 25 years? As a member of the life sciences, I’ve benefited from the crisp and succinct arguments you have put in your columns. Definitely shaped how I communicate as a physician and as a scientist. Thanks a million!

Vince Luca

Kudos to Vince Luca and the other laboratories for this achievement! Notch signaling is critical to epithelial, cancer, and T cell biology!

www.moffitt.org/research-sci...

Notching up a win: fresh tools for activating Notch Synthetic protein agonists could boost T-cell biomanufacturing and therapeutic strategies.

For us epithelial and progenitor cell biologists:
www.nature.com/articles/d41...

Opinion | My Last Column: Finding Hope in an Age of Resentment Where have all the good vibes gone?

Paul Krugman’s last column in the Times

www.nytimes.com/2024/12/09/o...

What’s it gonna be?

Colleagues:
We have one unfilled position for July 2025 in our ID fellowship program at Medical College of Wisconsin in Milwaukee. Interested candidates please DM me or email at id_info@mcw.edu.
#IDSky
#MedSky
Please amplify 🙏🙏

www.mcw.edu/departments/...

For all of those in the lung organoid field, add 100ug/mL holotransferrin to your growth media to boost your human adult AT2 cultures. Great example of how serendipity in a mouse model yields insight into human biology.

Ageing limits stemness and tumorigenesis by reprogramming iron homeostasis - Nature Studies using mouse models of lung adenocarcinoma identify an association between age, iron homeostasis and tumour initiation potential that involves NUPR1 and lipocalin-2.

New in @natureportfolio.bsky.social from the Tuomas Tammela Lab: how aging suppresses tumorigenesis and stemness in the lung by promoting functional iron insufficiency in the alveolar epithelium. Interestingly, this renders aged cells resistant to ferroptosis. #OncSky www.nature.com/articles/s41...

Same

Durvalumab Wins FDA Approval in Limited-Stage Small Cell Lung Cancer The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with limited-stage small cell lung cancer.

Durvalumab now FDA approved for limited stage #SCLC based on the phase III ADRIATIC trial showing a PFS and an OS benefit (HR 0.73) with 2y of durvalumab after completion of definitive chemoradiation (avoid concurrent use). #LCSM #OncSky

www.targetedonc.com/view/durvalu....

Hi everyone, for giving Tuesday I have set up a patient fund for assistance with the basics to complete curative intent cancer treatments. My patients often have incomplete treatments due to transportation or food issues, despite being fully insured. DM me if you can help! Repost to spread the word!

Bskypt | Bluesky Social Receipts Generate social receipts for you BlueSky activity.

Check out my BlueSky receipt at bskypt.vercel.app/ameens.bsky.social

nice

When Susan was diagnosed with lung cancer we quickly learned we had many unanswered questions. We launched the @23andme Lung Cancer Community with the intention of getting answers.

23andme.com/lung-cancer/

From Susan

As we embark on Thanksgiving week I want to take a moment to reflect on this year and my family. Unfortunately I lost my sister to lung cancer in August.

blog.youtube/inside-youtu...

Thanks! This is a great resource!

Mind if I'm included?

Congrats!

16%? I've heard 5% and recently 7% from @ryangentzler.bsky.social . Are numbers going up or it depends on where we look?

What do we need to do to achieve parity with mammograms? @ryangentzler.bsky.social

Next-generation combination approaches for immune checkpoint therapy - Nature Immunology In this Review, Sharma and colleagues describe the current landscape of combination therapies and discuss requirements for the development of effective combination strategies.

www.nature.com/articles/s41...

Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang

Ironically I recall a major motivation for Musk's acquisition of Twitter was to reduce censorship and promote free speech.

The unknown factor you didn't account for going to ruin your experiment

If interested in this list mark it 📌

“Nailing down” risk and improving outcomes in early-stage breast cancer Whether via the strain of academic advancement or hyper-competitive industry-funded drug-development landscape,1 there has been increasing focus to shift c

Nailing down risk in early stage breast cancer —with @coffeemommy.bsky.social and Dr. Kevin Kalinsky #OncSky #MedSky
doi.org/10.1093/jnci...

Figure 3. Percentile as a discriminator of high productivity versus low productivity